Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016382 (
flushing
)
6,387
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Adverse effects of intravenous anaesthetic drugs may be divided into local and general effects. The former include venous sequelae ranging from soreness on palpation on the day after the injection to thrombosis of the whole venous system of the arm. Frequency of venous sequelae for water-soluble anaesthetics 5 to 10%; drugs sparingly soluble in water are similar in this regard when solubilised in 'Cremophor EL'. Diazepam or etomidate dissolved in
propylene glycol
can produce venous reactions in about 25% of patients on the 3rd day and more by the 15th day if given directly into the vein, and are really only acceptable when injected in an infusion. The general adverse effects of anaesthetic agents include excitatory effects, as well as those on the cardiovascular and respiratory systems which are almost unavoidable. Excitatory effects are diminished by suitable premedication, and the cardiovascular and respiratory effects can be minimised by low dosage and slow administration. Cardiovascular effects of the muscle relaxants are also unavoidable with the drugs presently available, but further research should provide drugs with greater selectivity. More troublesome are the hypersensitivity reactions which occur with both the induction agents and the neuromuscular blocking drugs. These range in frequency from about 1 in 30,000 with the barbiturates to about 1 in 1000 with the 'Cremophor'-containing solutions of propanidid and alphaxalone/alphadolone. However, it appears that the barbiturate reactions are more severe and prolonged. The frequency of hypersensitivity reactions following muscle relaxants is difficult to assess because marked
flushing
is very common following tubocurarine and bronchospasm can frequently be due to passage of an endotracheal tube. In spite of the alarm created by these reactions, provided the patient is treated in the standard manner, the mortality should be low.
...
PMID:Adverse effects of intravenously administered drugs used in anaesthetic practice. 702 Nov 21
We employed hyperosmotic concentrations of penetrating cryoprotective agents (CPA) to store the isolated rat hearts unfrozen at subzero temperatures. The effect of acute exposure to CPA was assessed by
flushing
the hearts with CP-14, a cardioplegic solution, containing methanol (MeOH), ethanol (EtOH), ethylene glycol (EG), or
propylene glycol
(PG) for 2 min and reperfusing immediately with Krebs-Henseleit buffer in a working-heart model. The maximal doses that did not cause irreversible suppression of heart function were: MeOH, 1.78 M; EtOH, 1.27 M; EG, 0.84 M; and PG, 0.87 M. For nonfreezing storage, the hearts were flushed with CP-14 containing the highest tolerable concentrations of MeOH, EtOH, EG, or PG, stored for 6 h at -3.7, -2.8, and -1.4 degrees C, respectively, and then reperfused. Control cardiac output (CO) was 76.2 +/- 1.8 ml/min. Post-reperfusional recovery of CO was 86% in MeOH hearts, 82% in EtOH hearts, 76% in EG hearts, and 79% in PG hearts. Thus MeOH offered not only the least cardiac-suppressing effect but the lowest nonfreezing storage temperature. When storage time was extended, recovery and myocardial ATP level decreased with time in hearts flushed with CP-14 + 1.78 M MeOH and stored at -3.7 degrees C. The decay of function was faster than the decay of ATP level, suggesting energy was better preserved than function. The low return of function, however, may be related to CPA toxicity, osmotic stress, and ischemia/reperfusion injury. Nonfreezing storage at subzero temperatures using these CPAs may provide a novel approach to long-term cardiac preservation.
...
PMID:Subzero nonfreezing storage of the mammalian cardiac explant. I. Methanol, ethanol, ethylene glycol, and propylene glycol as colligative cryoprotectants. 840 87